Enterprise Value
1.404B
Cash
389M
Avg Qtr Burn
-23.79M
Short % of Float
16.90%
Insider Ownership
1.22%
Institutional Own.
88.11%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rapivab (peramivir) Details Influenza | Approved Quarterly sales | |
Orladeyo (Berotralstat) Details Rare genetic disease, Rare diseases, Hereditary angioedema | Approved Quarterly sales | |
BCX10013 (Oral Factor D inhibitor) Details Complement mediated diseases, Paroxysmal nocturnal hemoglobinuria | Phase 1 Update | |
BCX9250 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva | Failed Discontinued | |
Galidesivir (BCX4430) Details COVID-19 | Failed Discontinued | |
BCX9930 (Oral Factor D inhibitor) Details Paroxysmal nocturnal hemoglobinuria | Failed Discontinued |